세계의 액체 생검 시장(제7판)

Liquid biopsies have transformed cancer diagnostics by offering a minimally invasive method to analyze tumor-derived materials circulating in biological fluids. This approach provides critical insights for cancer detection, therapy selection, and disease monitoring, complementing or replacing traditional tissue biopsies and imaging techniques that often carry procedural risks and limitations.

Kalorama Information's "The Worldwide Market for Liquid Biopsy, 7th Edition" explores the full spectrum of clinical applications driving adoption, including early detection and screening, alternative testing when tissue biopsy is impractical, therapy personalization and monitoring for resistance, disease surveillance for progression and recurrence, and prognostic assessment.

Comprehensive Market Analysis

"The Worldwide Market for Liquid Biopsy, 7th Edition" delivers a detailed forecast of global liquid biopsy revenues from 2025 to 2030, segmented by:

• Geographic Region: North America, Europe, Asia, and Rest of World, with regional market shares and growth trends.
• Technology Type: Circulating Tumor DNA (ctDNA)-based, Circulating Tumor Cell (CTC)-based, Extracellular Vesicle and Exosome-based, Multi-Analyte-based, and other analyte-driven approaches, including comparative tables of advantages and limitations.
• Cancer Type: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and Other Cancers, with revenue forecasts and share analysis for each indication.
• Application: Diagnosis and Screening, Therapy Guidance, Minimal Residual Disease (MRD), and Disease Prognosis, supported by market sizing and growth projections.

Industry Insights and Competitive Landscape

The report profiles selected liquid biopsy tests currently available and in development, including ctDNA-based assays, CTC-based platforms, and multi-analyte solutions. It examines clinical versus research use and regulatory trends. Detailed chapters cover technology comparisons, analyte-specific market dynamics, and application-level opportunities, supported by over a dozen tables and figures illustrating revenue forecasts, market shares, and growth drivers.

Scope and Methodology

This report covers the global market for liquid biopsy testing. The market data pertains to global and regional revenues at the level of testing companies. This differs from most KI reports, which provide estimates at the level of IVD products. While systems and kits are not excluded, they were not the primary focus of this report. Most companies offer these tests as services.

The base year for data is 2025, with forecasts provided through 2030. Compound annual growth rates (CAGRs) are included for each segment.

Information and data on the global liquid biopsy market were obtained from a wide range of primary and secondary sources. Interviews were conducted with manufacturers of IVD products, clinical laboratory technicians, and other industry experts. Secondary sources included statistical and informational reports and articles from government agencies, trade associations, and independent publishing firms. Annual reports, public filings, and websites of leading companies were also reviewed to identify evolving product and market trends, assess competitive factors, and support the overall industry analysis. Selected Kalorama Information and Strategic Directions International (SDi) publications were also consulted for additional background and context. SDi is Kalorama Information's sister publishing brand with the Science and Medicine Group.

Table of Contents

Chapter 1: Executive Summary

• About Kalorama Information
• Scope and Methodology
• Introduction
• Liquid Biopsy Technologies
• Industry Structure
• Liquid Biopsy Market Revenues and Forecast
  • Figure 1-1: Global Market for Liquid Biopsy, 2025-2030 ($ million)
  • Figure 1-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 (%)
  • Figure 1-3: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]

Chapter 2: Liquid Biopsy Technologies

• Introduction
• Major Liquid Biopsy Technologies

Chapter 3: Circulating Tumor DNA (ctDNA) Liquid Biopsy

• Introduction
• Advantages and Limitations of ctDNA in Liquid Biopsy
• ctDNA-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • LungLife AI
  • Myriad Genetics
  • Natera
  • NeoGenomics
  • OncoDNA
  • Personal Genome Diagnostics (Labcorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
• ctDNA-based Liquid Biopsy Tests in Development
  • BillionToOne
  • Cyclomics
  • Exact Sciences
  • Freenome
  • GRAIL

Chapter 4: Circulating Tumor Cells (CTCs) Liquid Biopsy

• Introduction
• Challenges in the Development of CTC-based Liquid Biopsy Tests
• CTC-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
• Selected CTC-based Liquid Biopsy Tests in Development
  • BioFluidica
  • Epic Sciences
  • QCDx

Chapter 5: Extracellular Vesicles and Other Liquid Biopsy

• Introduction
• Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
  • Biodesix
  • Exosome Diagnostics
  • Mercy BioAnalytics
• Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
  • EValuate Diagnostics
  • Insight Molecular Diagnostics (formerly OncoCyte)
  • Nanostics
  • VolitionRx

Chapter 6: Multi-Analyte Liquid Biopsy Tests

• Introduction
• Liquid Biopsy Tests Based on Multiple Analytes
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
• Multiple Analyte-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

Chapter 7: Liquid Biopsy Tests for Research Use Only

• Introduction
• Liquid Biopsy Tests for Research Use Only
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • QIAGEN

Chapter 8: Liquid Biopsy Industry Analysis

• Introduction
• Tiers of Competition
• Competitive Factors
• Significant Market Trends
• Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
• Competitors No Longer in the Liquid Biopsy Market

Chapter 9: Liquid Biopsy Market

• Market Overview
  • Figure 9-1: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]
  • Regional Market Overview
    • Figure 9-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 vs. 2030 (%)
  • Clinical vs. Research Use
• Market Forecast

Chapter 10: Market by Analyte

• Overall
  • Analyte Analysis
    • Figure 10-1: Global Liquid Biopsy Market, by Analyte, 2025 vs. 2030 ($ million) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
    • Figure 10-2: Global Liquid Biopsy Market, Share by Analyte, 2025 vs. 2030 (%) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
• Circulating Tumor DNA
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
  • Circulating Tumor Cells
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Extracellular Vesicles and Other Analytes
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Multiple Analytes
  • Market Overview
  • Revenue Forecast

Chapter 11: Market by Application

• Overview
  • Application Analysis
    • Figure 11-1: Global Liquid Biopsy Market, by Application, 2025 vs. 2030 ($ million) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
    • Figure 11-2: Global Liquid Biopsy Market, Share by Application, 2025 vs. 2030 (%) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
• Therapy Guidance and Monitoring
  • Market Overview
  • Revenue Forecast
  • Minimal Residual Disease (MRD)
  • Market Overview
  • Revenue Forecast
• Diagnosis/Screening
  • Market Overview
  • Revenue Forecast
• Disease Prognosis
  • Market Overview
  • Revenue Forecast

Chapter 12: Market by Cancer Type

• Overall
  • Cancer Type Analysis
    • Figure 12-1: Global Liquid Biopsy Market, by Cancer Type, 2025 vs. 2030 ($ million) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
    • Figure 12-2: Global Liquid Biopsy Market, Share by Cancer Type, 2025 vs. 2030 (%) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
• Pan-Cancer Tests
  • Market Overview
  • Revenue Forecast
• Lung Cancer
  • Market Overview
  • Revenue Forecast
• Prostate Cancer
  • Market Overview
  • Revenue Forecast
• Colorectal Cancer
  • Market Overview
  • Revenue Forecast
• Breast Cancer
  • Market Overview
  • Revenue Forecast
• Ovarian Cancer
  • Market Overview
  • Revenue Forecast
• Other Cancers
  • Market Overview
  • Revenue Forecast

Chapter 13: Company Profiles

• Adaptive Biotechnologies
• Agena Bioscience, Inc.
• ANGLE plc
• Aspira Women's Health
• Biocartis Group NV
• Biodesix
• CellMax Life
• Circulogene
• DiaCarta, Inc.
• Epic Sciences
• Exact Sciences
• Freenome, Inc.
• GILUPI GmbH
• GRAIL
• Guardant Health, Inc.
• Hologic
• LungLife AI (formerly Cynvenio Biosystems)
• MDxHealth
• Menarini-Silicon Biosystems, Spa
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA S.A.
• Personal Genome Diagnostics
• QIAGEN N.V.
  • Cell-free DNA Technologies
  • CTC Technologies
  • Exosome and miRNA Technologies
• Resolution Biosciences (Exact Sciences)
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus AI